Experimental gene therapy targets eye neurons to restore vision

Life Biosciences has developed ER-100, an experimental gene therapy that aims to restore vision by rejuvenating damaged retinal neurons using epigenetic reprogramming. The therapy targets optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy, by resetting aging retinal cells. ER-100 has shown promising results in preclinical studies, improving visual function in animal models. The therapy received FDA approval for a first-in-human trial, which will focus on safety and early signs of benefit. If successful, ER-100 could represent a significant advancement in treating age-related eye diseases.